Oncotarget

Research Papers:

STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer

Xiaoman Li, Lufeng Zheng, Feng Zhang, Jinhang Hu, Jinjiang Chou, Yu Liu, Yingying Xing and Tao Xi _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:23197-23211. https://doi.org/10.18632/oncotarget.8099

Metrics: PDF 1345 views  |   HTML 2787 views  |   ?  


Abstract

Xiaoman Li1,2,*, Lufeng Zheng1,2,*, Feng Zhang1,2, Jinhang Hu1,2, Jinjiang Chou1,2, Yu Liu3, Yingying Xing1,2 and Tao Xi1,2

1 School of Life Science and Technology, China Pharmaceutical University, Nanjing, People′s Republic of China

2 Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People′s Republic of China

3 Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing, People′s Republic of China

* These authors have contributed equally to this work

Correspondence to:

Tao Xi, email:

Yingying Xing, email:

Keywords: STARD13; 3′UTRs; ceRNA; breast cancer metastasis; EMT

Received: December 11, 2015 Accepted: February 28, 2016 Published: March 15, 2016

Abstract

Competing endogenous RNAs (ceRNAs) network has been correlated with the initiation and development of cancer. Here, we identify CDH5, HOXD1, and HOXD10 as putative STARD13 ceRNAs and they display concordant patterns with STARD13 in different metastatic potential breast cancer cell lines and tissues. Notably, 3′UTRs of these genes suppress breast cancer metastasis via inhibiting epithelial-mesenchymal transition (EMT) in vitro and in vivo, which are activated through the crosstalk between STARD13 and its ceRNAs in 3′UTR- and miRNA-dependent manners. In addition, Kaplan-Meier survival analysis reveals that mRNA level of STARD13 and its ceRNAs is remarkably associated with survival of breast cancer patients. These results suggest that 3′UTRs of CDH5, HOXD1, and HOXD10 inhibit breast cancer metastasis via serving as STARD13 ceRNAs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8099